Informed Consent and Bisphosphonate Risk
A 67-year-old patient on bisphosphonate therapy (alendronate) for osteoporosis for the past seven years presents requiring extraction of an unrestorable maxillary molar. Communicating a risk of roughly 0.1-0.5% (the AAOMS estimate for MRONJ after tooth extraction in patients on oral bisphosphonates is approximately 0.5%; observational series report lower): contextualizing statistical risk is a known communication challenge.
The most useful approaches pair the percentage with a concrete comparison ('Roughly 1 in 200 to 1 in 1,000 extractions in patients on your medication are associated with this complication') and explain what the outcome means in human terms ('It would mean a slow-healing wound at the extraction site that requires specialist management — it is serious but manageable when caught early').
Note that this extraction-specific figure is much higher than the background rate of this complication in everyone taking the drug, which is what the low headline numbers usually refer to.
Do not minimize but do not catastrophize — the goal is calibrated understanding. of dental extractions in patients on long-term bisphosphonate therapy — particularly intravenous bisphosphonates, though oral bisphosphonates also carry risk after long-term use. The patient is not aware of this risk.
How do you conduct the informed consent conversation for this procedure, and what clinical steps would you take to minimize risk?
Likely follow-up · The patient asks: 'How likely is this to happen to me?'
You know the absolute risk of BRONJ from oral bisphosphonates is low but not zero — Communicating a risk of roughly 0.1-0.5% (the AAOMS estimate for MRONJ after tooth extraction in patients on oral bisphosphonates is approximately 0.5%; observational series report lower): contextualizing statistical risk is a known communication challenge.
The most useful approaches pair the percentage with a concrete comparison ('Roughly 1 in 200 to 1 in 1,000 extractions in patients on your medication are associated with this complication') and explain what the outcome means in human terms ('It would mean a slow-healing wound at the extraction site that requires specialist management — it is serious but manageable when caught early').
Note that this extraction-specific figure is much higher than the background rate of this complication in everyone taking the drug, which is what the low headline numbers usually refer to. Do not minimize but do not catastrophize — the goal is calibrated understanding..
How do you communicate this probability in a way that is accurate and useful to the patient rather than creating disproportionate alarm or false reassurance?